

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ATEA PHARMACEUTICALS, INC.
Petitioner,

v.

GILEAD SCIENCES, INC.
Patent Owner.

PGR2023-00046
U.S. Patent No. 11,642,361

PATENT OWNER'S EXHIBIT LIST

Ex. No.	Description
2001	“FDA Approves Gilead's Hepatitis C Drug”, Wall Street Journal (December 6, 2013)
2002	“F.D.A. Approves Pill to Treat Hepatitis C”, NYTimes (December 7, 2013)
2003	“Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts”, Gilead Press Release (April 3, 2023)
2004	“U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C”, Gilead Press Release (December 6, 2013)
2005	Young et al., “Hepatitis C Protease and Polymerase Inhibitors in Development”, AIDS PATIENT CARE and STDs, Vol. 22, No. 6 (2008)
2006	Clark et al., “Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication”, J. Med. Chem. 2005, 48, 5504-5508
2007	U.S. Patent No. 7,429,572
2008	U.S. Patent No. 8,815,830
2009	Reserved
2010	Reserved
2011	Reserved
2012	U.S. Patent No. 8,735,372
2013	U.S. Patent No. 8,906,880
2014	U.S. Patent No. 8,957,046
2015	Partial file history for U.S. Patent No. 7,964,580

Ex. No.	Description
2016	Partial file history for U.S. Patent No. 8,334,270
2017	Partial file history for U.S. Patent No. 8,580,765
2018	Partial file history for U.S. Patent No. 9,085,573
2019	Partial file history for U.S. Patent No. 9,585,906
2020	Partial file history for U.S. Patent No. 10,183,037
2021	File history for U.S. Patent App. No. 16/169,878
2022	File history for U.S. Patent App. No. 16/516,192
2023	File history for U.S. Patent App. No. 16/817,318
2024	Partial file history for U.S. Patent No. 8,735,372
2025	Partial file history for U.S. Patent No. 8,906,880
2026	Partial file history for U.S. Patent No. 8,957,046
2027	Gilead Sciences v. Nucana PLC [2023] EWHC 611 (Pat); Case No: HP-2021-000007 (Approved Judgment).
2028	“Hepatitis C replicon system and drug development”, 2016 Lasker-DeBakey Clinical Medical Research Award, available at: https://laskerfoundation.org/winners/hepatitis-c-replicon-system-and-drug-development/
2029	File history for U.S. Patent No. 11,642,361
2030	File history excerpts of Utility Patent Application Transmittal Sheets for Idenix Pharmaceuticals, Inc.’s U.S. Patent Nos. 6,914,054; 7,608,597; and 7,608,600
2031	Atea Pharmaceuticals Founder, Chairman & CEO: Jean-Pierre Sommadossi available at: https://ateapharma.com/team_members/jean-pierre-sommadossi/

Ex. No.	Description
2032	U.S. Patent No. 6,914,054
2033	U.S. Patent No. 7,608,597
2034	U.S. Patent No. 7,608,600
2035	Jinfa Du LinkedIn Profile
2036	Dhanapalan Nagarathnam LinkedIn Profile
2037	Michael Sofia LinkedIn Profile
2038	Peiyuan Wang LinkedIn Profile

Respectfully submitted,

Dated: November 22, 2023

Cooley LLP
1299 Pennsylvania Avenue, NW
Suite 700
Washington, DC 20004-2400
T: 858-550-6019
F: 858-550-6420
Email: cshear@cooley.com

/William C. Shear/
William C. Shear
Reg. No. 47,938

Attorney for Patent Owner

CERTIFICATE OF SERVICE

Pursuant to 37 CFR §§ 42.6(e)(4) and 42.205(b), the undersigned certifies that on November 22, 2023, a copy of the foregoing Patent Owner's Exhibit List and Exhibits 2001-2038 were served via electronic mail on the Petitioner by serving Petitioner's counsel of record as follows:

Sherry M. Knowles
Anthony R. Prosser, Ph.D.
Brent R. Bellows, Ph.D.
KNOWLES IP STRATEGIES, LLC
sknowles@kipsllc.com
tprosser@kipsllc.com
bbellows@kipsllc.com

Dated: November 22, 2023

/William C. Shear/

William C. Shear

Reg. No. 47,938